Directive (EU) 2024/3019 makes drug manufacturers financially responsible for removing pharmaceutical residues from wastewater and introduces stricter, standardized monitoring requirements that are set to increase demand for trace-level analytical expertise.
Europe’s pharmaceutical industry is preparing for a major shift in how it accounts for drug residues in the environment according to a recent blog entry on the Veolia (a French multinational company that provides water, waste, and energy management services to help municipalities and industries conserve and replenish resources) website , and analytical laboratories are likely to feel the effects. Directive (EU) 2024/3019 redraws environmental sustainability priorities for the sector, introducing stricter monitoring requirements, a new tier of wastewater treatment, and a principle that makes drug manufacturers financially responsible for removing the micropollutants their products leave behind.
At the heart of the directive is extended producer responsibility (EPR). Under this approach, pharmaceutical companies must take part in a centralized organization that collectively manages their EPR obligations. Through it, they will help fund investment in advanced wastewater treatment, along with the systems used to monitor micropollutants and to collect and verify the resulting data. The change marks a significant departure from earlier practice, shifting the burden of dealing with pharmaceutical residues toward the companies that produce them.
For analytical scientists, the most relevant provisions concern monitoring. The directive calls for measuring the concentrations of specific pharmaceutical substances in wastewater and assessing how effectively treatment processes remove them. To make results transparent and comparable across facilities and member states, companies will need to adopt standardized analytical methods.
That requirement is likely to increase demand for robust, validated methods capable of quantifying drug residues at trace levels in complex wastewater matrices, along with harmonized procedures for sampling, quality control, and data reporting. Measuring removal efficiency also means analyzing samples both before and after treatment, which will place a premium on accuracy and reproducibility at low concentrations.
The directive also introduces quaternary treatment, an additional stage beyond conventional processes designed specifically to remove micropollutants. Plants using it will need to remove 80% of at least six target substances. Large treatment plants will begin implementing it from 2033, with requirements extending progressively through 2045. The phased schedule is intended to give operators and manufacturers time to plan and install the necessary technology without disrupting operations.
Because compliance hinges on demonstrating that 80% removal threshold, analytical data will be central to showing whether treatment is working as required.
Smaller manufacturers will receive some relief. Facilities producing less than 1 ton per year are exempt, a provision designed to protect small and medium-sized enterprises from costs that could otherwise prove prohibitive while keeping overall environmental standards high.
The industry faces a clear timeline. Technical criteria for exemptions are due to be defined in 2027, the EPR system is set to come into force in 2028, and quaternary treatment will be phased in between 2033 and 2045.
Beyond monitoring, the directive is expected to prompt broader changes across the pharmaceutical life cycle. Companies will need to overhaul their environmental management systems and adopt new traceability technologies, and in some cases they may need to reformulate drugs to reduce their environmental impact, a process that demands time, resources, and specialized expertise.
The financial impact could be substantial. Investment in monitoring and control systems, together with research into more sustainable products, may raise production costs in the short term, with possible knock-on effects for medicine prices. Over the longer term, however, these investments could improve efficiency and offer a competitive edge.
The rules are also accelerating interest in “green by design” pharmaceuticals, in which environmental considerations are built into drug development from the earliest stages. Closer cooperation between drug manufacturers and water utilities is creating opportunities for new partnerships, with some companies exploring consortia to jointly manage treatment plants and others investing in shared research programs aimed at reducing environmental impact.
Taken together, these changes point to a growing role for environmental analysis in pharmaceutical compliance. As standardized monitoring becomes mandatory and removal targets tighten, laboratories with expertise in trace-level quantitation of pharmaceutical residues, method validation, and data management are likely to be in increasing demand, both within the industry and among the water utilities and service providers working alongside it.
Veolia, a global leader in environmental services, works every day to build environmental security for the benefit of public health and the competitiveness of industries and regions. With 215,000 employees across five continents, working closely with local communities, and thanks to its cutting-edge technologies, the group cleans up pollution, reduces carbon emissions, and regenerates resources through concrete solutions that combine its expertise in water and water technologies, waste - including hazardous waste management, and local energy. In 2025, the Veolia group served 110 million people with drinking water and 97 million with sanitation, produced 45 million megawatt hours of energy, and treated 64 million tons of waste.2
References
